| Results have been mixed for remdesivir in studies of COVID-19, but it is the first effective therapy for COVID-19 regarding shortening time to recovery. |
| Limited availability of remdesivir requires clinicians to face difficult decisions when prioritizing patients. |
| This report summarizes and aggregates the available clinical data to aid in clinical decision-making for remdesivir therapy. |
| Remdesivir is generally well tolerated with comparable rates of adverse events to placebo. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.